MONSTAR-SCREEN-3 preliminary cohort included gastric and esophageal cancers
The ASCO 2025 preliminary MONSTAR-SCREEN-3 ctDNA report included 22 patients with gastric cancer and 8 with esophageal cancer among 114 patients across 15 cancer types.
Cancer type
Gastric and esophageal cancer.
1
Cabalag et al. Annals of Surgery. 2022.
ctDNA was assessed against CT and PET for prognosis, response to neoadjuvant therapy, and surveillance for recurrence in esophageal adenocarcinoma.
A randomized ctDNA-guided gastroesophageal trial was not identified.
Listed when a study is a randomized or prospective interventional ctDNA or MRD trial, is cited in NCCN or ESMO guidance, or is a prospective validation cohort in a high-impact journal. Shorter lists mean fewer studies met that rule. No test is ranked.
Tier 2 · Level 2 · Cancer Communications · 2023
Yuan SQ, et al. PMID 37837629 · doi 10.1002/cac2.12494
A prospective cohort of 100 people with stage II or III resectable gastric cancer collected tumor and perioperative plasma to test whether ctDNA after adjuvant chemotherapy predicted recurrence. The abstract does not name the assay.
Tier 3 · Level 3 · Scientific Reports · 2026
Nixon AB, et al. PMID 41872254 · doi 10.1038/s41598-026-43178-4
NeXT Personal was applied to 24 people with metastatic esophagogastric cancer in the phase 2 KeyLargo study, and every patient was ctDNA-positive at baseline.
Tier 3 · Level 3 · Gastric Cancer · 2025
Iden CR, et al. PMID 39369091 · doi 10.1007/s10120-024-01556-9
ctDNA was studied as a recurrence-risk marker in people with resectable gastric and gastroesophageal junction adenocarcinoma receiving perioperative chemotherapy. The abstract does not name the assay.
Tier 4 · Level 3 · Clinical Cancer Research · 2026-11-03 · Peer-reviewed · Verified
Hidalgo AM, et al. PMID 42975193 · doi 10.1158/1078-0432.CCR-26-3052
Commentary
This commentary discusses an ultrasensitive MAESTRO analysis of 331 plasma samples from 36 patients with esophageal cancer treated with curative intent. It reports that 60% of ctDNA-positive samples were below 100 parts per million, and that every recurrence was preceded by postoperative ctDNA detection. These figures are quoted from the commentary's account of the underlying article.
Accruing studies for Gastroesophageal
The ASCO 2025 preliminary MONSTAR-SCREEN-3 ctDNA report included 22 patients with gastric cancer and 8 with esophageal cancer among 114 patients across 15 cancer types.